ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 950,17
0,11%
Dow Jones
44 544,66
-0,75%
DAX
21 732,05
0,01%
Brent Oil
76,385
0,00%
Bitcoin
101 861,82
-0,54%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. 60 Degrees Pharmaceuticals Inc (SXTP)

  7. 60 Degrees Pharmaceuticals Inc (SXTP) Actualités

SXTP

60 Degrees Pharmaceuticals (SXTP)

60 Degrees Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SXTP
DateHeureSourceTitreSymboleSociété
30/01/202520h20GlobeNewswire Inc.60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
29/01/202514h00GlobeNewswire Inc.60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
28/01/202514h01GlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
08/01/202514h02GlobeNewswire Inc.60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) BabesiosisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
23/12/202414h57GlobeNewswire Inc.Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and PreventionNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
11/12/202414h56GlobeNewswire Inc.60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s HospitalNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/11/202420h31GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Third Quarter 2024 ResultsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
03/10/202415h02GlobeNewswire Inc.60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. LaunchNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
06/09/202414h59GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
04/09/202414h00GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
28/08/202421h59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
28/08/202420h48GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing RequirementsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/08/202417h01GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Second Quarter 2024 ResultsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/08/202416h29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
12/08/202415h12GlobeNewswire Inc.60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb StudyNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
06/08/202415h26GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock SplitNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
02/08/202422h15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
25/07/202415h02GlobeNewswire Inc.60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade SupportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
19/07/202414h29GlobeNewswire Inc.60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis StudyNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
19/07/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
12/07/202423h02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
09/07/202412h31GlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior TreatmentNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
27/06/202413h59GlobeNewswire Inc.First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its KindNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
11/06/202413h59GlobeNewswire Inc.60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute BabesiosisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
30/05/202413h59GlobeNewswire Inc.Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its KindNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
20/05/202413h59GlobeNewswire Inc.60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine StudyNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
15/05/202419h45GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces First Quarter 2024 ResultsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
08/05/202413h59GlobeNewswire Inc.60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious DiseasesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
02/05/202413h59GlobeNewswire Inc.60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes RequiredNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
03/04/202413h58GlobeNewswire Inc.60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine BabesiosisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SXTP

Dernières Valeurs Consultées

LSE
0HOB
H & R Block
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces